Tes Pharma Presents Results on TES-4207 at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
Solomeo-Corciano (PG), Italy, December 10, 2025 – Tes Pharma, a biotech company focused on delivering first-in class therapeutics for high unmet medical needs in oncological, metabolic and renal diseases, today announced that a poster presentation will be delivered on the Company’s product candidate TES-4207 (former TES-ONC-07) at the ESMO Immuno-Oncology Congress 2025 taking place December 10-12, 2025, in London, UK.
“I am excited to present new findings on our lead compound TES-4207, which is currently being explored as a novel strategy in cancer immunotherapy,” said Andrea Pellacani, Chief Medical Officer at Tes Pharma. “Our new data further support that targeting the orphan nuclear receptor NR2F6 can significantly boost immune cell infiltration into tumors and enhance their ability to fight cancer cells, even in models that do not respond to existing immune checkpoint inhibitors”
Title: TES-4207, a First-in-Class Antagonist of the Immune Checkpoint NR2F6,
Drives Anti-Tumor Immunity and Enhances Efficacy of PD-1 Blockade
Lead Author: Greco Francesco A., PhD, NR2F6 Project Leader, Tes Pharma
Date/Time: Wednesday, December 10, 2025, from: p.m. 5:30–6:30 p.m. GMT
More information about this abstract will be made available after the respective embargoes, as set by the ESMO organizers, are lifted for each presentation.
About TES-4207
TES-4207 is a potent and selective first-in-class modulator of the orphan nuclear receptor NR2F6. This protein is upregulated in tumor infiltrating lymphocytes (TILs), and it has emerged as a key factor that reduces the activation of TILs against cancer. Since NR2F6 expression is limited in peripheral immune cells, it represents a tumor-inducible valuable target for novel immunotherapy approaches. Indeed, NR2F6 expression inversely correlates with reduced immune infiltration in several human cancers.
Treatment with TES-4207 increases activation levels of T cells ex vivo and immune infiltration in “cold” tumors, resulting in reduced cancer growth in immunotherapy-resistant cancer models,
About Tes Pharma
Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in renal, metabolic and oncological disease. The company’s lead compound TESP-0401, demonstrated significant effect in models of kidney disease and is planned to initiate first-in human studies in 2026. The company’s lead oncology programs are TES-4207 for cancer immunotherapy and TES-5999. Tes Pharma has a partnership with Alfasigma for the development of INT-787 for the treatment of severe alcohol-associated hepatitis (sAH), currently in Phase 2. Also, the company has an undisclosed pipeline of additional projects in the early phase of drug discovery.
For more information, please visit www.tespharma.com or connect with the Company on LinkedIn
For further information, please contact:
Sara Malincarne
smalincarne@tespharma.com